August 02, 2016 08:30 AM Eastern Daylight Time. August 02, 2016.
First Gene Therapy Candidate to Receive Designation for FA.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Agilis’ gene therapy product candidate, AGIL-FA, being developed for the treatment of Friedreich’s ataxia (FA).
Subscribe to:
Posts (Atom)
